Perhaps someone more knowledgeable could clarify the following:
- If at the 45% readout (or even the 60%) it is deemed that the treatment is showing outstanding results (as we all expect and hope for ) ie "Overwhelming efficacy" and the decision is made to continue the trial, does it continue with the placebo arm?
- I ask as effectively that would be subjecting those remaining to be enlisted (to complete the trial) with a 50:50 chance of survival (obviously not exactly 50:50 due to improved SOC and Rem-l may not be 100% effective).
- It does raise ethical questions
- Is there any obligation to inform the market (company) or could/would they just announce "the trial is continuing" with out any reference to the results?
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-218
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.008(0.68%) |
Mkt cap ! $1.278B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.10 | $5.176M | 4.627M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 67714 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 39353 | 13 |
View Market Depth
| Last trade - 13.44pm 08/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |